Literature DB >> 24439270

Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis.

Jean Addington1, Hely Shah2, Lu Liu3, Donald Addington3.   

Abstract

Assessment of depression in individuals who are considered to be at clinical high risk (CHR) for psychosis is important as high rates of depression have been reported in CHR individuals. The Calgary Depression Scale (CDSS) is the most widely used scale for assessing depression in schizophrenia. It has excellent psychometric properties, internal consistency, inter-rater reliability, sensitivity, specificity, and discriminant and convergent validity. The aim of this study was to test the reliability and validity of the CDSS in a sample of youth at CHR for psychosis. Participants were assessed for depression, presence of axis 1 mood disorders, and prodromal symptoms using the CDSS, the Structured Clinical Interview for DSM-IV Disorders (SCID-1), and the Scale of Prodromal Symptoms (SOPS). The CDSS total score as well as all individual items, except "guilty ideas of reference," were significantly associated with the presence of a major depressive disorder. Significant correlations were observed between CDSS total score and the dysphoric mood item on the SOPS. There was some evidence of overlap between the CDSS and both attenuated positive symptoms and negative symptoms as assessed by the SOPS. It is concluded that CDSS is a reliable scale suitable for assessing depression in individuals considered to be at CHR for psychosis.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Calgary Depression Scale for Schizophrenia; Clinical high risk; Depression; Psychosis; Schizophrenia

Mesh:

Year:  2014        PMID: 24439270      PMCID: PMC3982913          DOI: 10.1016/j.schres.2013.12.014

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  26 in total

Review 1.  Prediction and prevention of psychosis in youth at clinical high risk.

Authors:  Jean Addington; Robert Heinssen
Journal:  Annu Rev Clin Psychol       Date:  2011-12-12       Impact factor: 18.561

2.  The early course of schizophrenia and depression*.

Authors:  Heinz Häfner; Kurt Maurer; Günter Trendler; Wolfram an der Heiden; Martin Schmidt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

3.  The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G).

Authors:  M J Müller; P Marx-Dannigkeit; R Schlösser; H Wetzel; D Addington; O Benkert
Journal:  J Psychiatr Res       Date:  1999 Sep-Oct       Impact factor: 4.791

4.  Mood symptoms, cognition, and everyday functioning: in major depression, bipolar disorder, and schizophrenia.

Authors:  Philip D Harvey
Journal:  Innov Clin Neurosci       Date:  2011-10

5.  Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS).

Authors:  C Lançon; P Auquier; G Reine; D Bernard; M Toumi
Journal:  J Affect Disord       Date:  2000-05       Impact factor: 4.839

6.  A depression rating scale for schizophrenics.

Authors:  D Addington; J Addington; B Schissel
Journal:  Schizophr Res       Date:  1990 Jul-Aug       Impact factor: 4.939

7.  Calgary Depression Scale for Schizophrenia: a study of the validity of a French-language version in a population of schizophrenic patients.

Authors:  D Bernard; C Lançon; P Auquier; G Reine; D Addington
Journal:  Acta Psychiatr Scand       Date:  1998-01       Impact factor: 6.392

8.  Specificity of the Calgary Depression Scale for schizophrenics.

Authors:  D Addington; J Addington; E Maticka-Tyndale
Journal:  Schizophr Res       Date:  1994-02       Impact factor: 4.939

Review 9.  Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.

Authors: 
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

10.  Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis.

Authors:  Paolo Fusar-Poli; Barnaby Nelson; Lucia Valmaggia; Alison R Yung; Philip K McGuire
Journal:  Schizophr Bull       Date:  2012-11-22       Impact factor: 9.306

View more
  30 in total

1.  Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers.

Authors:  Nikolaos Koutsouleris; Eva M Meisenzahl; Stefan Borgwardt; Anita Riecher-Rössler; Thomas Frodl; Joseph Kambeitz; Yanis Köhler; Peter Falkai; Hans-Jürgen Möller; Maximilian Reiser; Christos Davatzikos
Journal:  Brain       Date:  2015-05-01       Impact factor: 13.501

2.  Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction.

Authors:  Kristin M Healey; David L Penn; Diana Perkins; Scott W Woods; Richard S E Keefe; Jean Addington
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

3.  The Violent Content in Attenuated Psychotic Symptoms.

Authors:  Catherine Marshall; Stephanie Deighton; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel Mathalon; Jean Addington
Journal:  Psychiatry Res       Date:  2016-05-07       Impact factor: 3.222

4.  Sleep problems and attenuated psychotic symptoms in youth at clinical high-risk for psychosis.

Authors:  Katrina B Goines; Allison M LoPilato; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Scott W Woods; Elaine F Walker
Journal:  Psychiatry Res       Date:  2019-08-03       Impact factor: 3.222

5.  Inefficient effort allocation and negative symptoms in individuals with schizophrenia.

Authors:  Julie M McCarthy; Michael T Treadway; Melanie E Bennett; Jack J Blanchard
Journal:  Schizophr Res       Date:  2016-01-04       Impact factor: 4.939

6.  Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study.

Authors:  Larry J Seidman; Daniel I Shapiro; William S Stone; Kristen A Woodberry; Ashley Ronzio; Barbara A Cornblatt; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods
Journal:  JAMA Psychiatry       Date:  2016-12-01       Impact factor: 21.596

7.  Persistent negative symptoms in youth at clinical high risk for psychosis: A longitudinal study.

Authors:  D J Devoe; L Lu; T D Cannon; K S Cadenhead; B A Cornblatt; T H McGlashan; D O Perkins; L J Seidman; M T Tsuang; S W Woods; E F Walker; D H Mathalon; C E Bearden; J Addington
Journal:  Schizophr Res       Date:  2020-04-30       Impact factor: 4.939

8.  Effects of Oxytocin on Emotion Recognition in Schizophrenia: A Randomized Double-Blind Pilot Study.

Authors:  Elissar Andari; Nicholas M Massa; Molly D Fargotstein; Nicholas B Taylor; David M Halverson; Andrew V Owens; Danielle L Currin; Arpita Bhattacharya; Dmitriy Gitman; Bruce C Cuthbert; Larry J Young; Erica J Duncan
Journal:  J Clin Psychopharmacol       Date:  2021 Mar-Apr 01       Impact factor: 3.153

9.  Depression, family interaction and family intervention in adolescents at clinical-high risk for psychosis.

Authors:  Gabrielle R Rinne; Mary P O'Brien; David J Miklowitz; Jean M Addington; Tyrone D Cannon
Journal:  Early Interv Psychiatry       Date:  2020-03-30       Impact factor: 2.732

10.  Depression: An actionable outcome for those at clinical high-risk.

Authors:  Jean Addington; Megan S Farris; Lu Liu; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Carrie E Bearden; Daniel H Mathalon; William S Stone; Matcheri Keshevan; Scott W Woods
Journal:  Schizophr Res       Date:  2020-10-29       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.